Potential Application of Cord Blood-Derived Stromal Cells in Cellular Therapy and Regenerative Medicine

Abstract EN

Neonatal stromal cells from umbilical cord blood (CB) are promising alternatives to bone marrow- (BM-) derived multipotent stromal cells (MSCs).

In comparison to BM-MSC, the less mature CB-derived stromal cells have been described as a cell population with higher differentiation and proliferation potential that might be of potential interest for clinical application in regenerative medicine.

Recently, it has become clear that cord blood contains different stromal cell populations, and as of today, a clear distinction between unrestricted somatic stromal cells (USSCs) and CB-MSC has been established.

This classification is based on the expression of DLK-1, HOX, and CD146, as well as functional examination of the adipogenic differentiation potential and the capacity to support haematopoiesis in vitro and in vivo.

However, a marker enabling a prospective isolation of the rare cell populations directly out of cord blood is yet to be found.

Further analysis may help to reveal even more subpopulations with different properties, which could be useful for the directed application of these cells in preclinical models.